A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Phase 1/2 Completed
47 enrolled 36 charts
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
Phase 1 Completed
21 enrolled
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Phase 1 Completed
49 enrolled
U01CA236220
Phase 1/2 Completed
37 enrolled
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Phase 1/2 Completed
316 enrolled
A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Phase 1/2 Completed
21 enrolled
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Phase 1/2 Completed
36 enrolled
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Phase 1 Completed
62 enrolled
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Phase 1/2 Completed
76 enrolled 25 charts
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Phase 3 Completed
481 enrolled 21 charts
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Phase 2 Completed
22 enrolled 13 charts
EW-2
Phase 2 Completed
155 enrolled
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Phase 1/2 Completed
40 enrolled 30 charts
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Phase 1 Completed
34 enrolled
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
Phase 1 Completed
16 enrolled
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Phase 3 Completed
109 enrolled 12 charts
VIT-0910
Phase 2 Completed
120 enrolled
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
123 enrolled 16 charts
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Phase 2 Completed
175 enrolled 13 charts
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
Phase 1 Completed
7 enrolled
Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
Phase 1/2 Completed
58 enrolled
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Phase 1 Completed
21 enrolled
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Completed
17 enrolled
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Phase 1 Completed
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
Phase 2 Completed
20 enrolled
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
Phase 2 Completed
68 enrolled
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Phase 2 Completed
125 enrolled 9 charts
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Phase 2 Completed
41 enrolled 10 charts
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma
Phase 2 Completed
77 enrolled
Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2 Completed
170 enrolled
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma
Phase 2 Completed
35 enrolled
Irinotecan in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Phase 1 Completed
96 enrolled
Irinotecan in Treating Children With Refractory Solid Tumors
Phase 2 Completed
181 enrolled
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
Phase 2 Completed
150 enrolled
Irinotecan (Camptosar) in Patients With Advanced Sarcomas
Phase 2 Completed
38 enrolled
Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy
Phase 2 Completed
26 enrolled
Carboplatin Plus Irinotecan in Treating Patients With Glioblastoma Multiforme
Phase 2 Completed